Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone replacement therapy

J E Compston1

  • 1Department of Medicine, University of Cambridge School of Clinical Medicine, UK.

Bailliere'S Clinical Rheumatology
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Hormone replacement therapy (HRT) prevents menopausal bone loss and reduces fracture risk. Long-term HRT may be needed for maximum protection, with emerging treatments offering benefits without side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

People living with HIV and fracture risk.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Self-perception of fracture risk: what can it tell us?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2013
Same author

Bone densitometry and clinical decision making.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2013
Same author

An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.

Archives of osteoporosis·2012
Same author

Treatment failure in osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2012
Same journal

Regional soft tissue pains: alias myofascial pain?

Bailliere's clinical rheumatology·1999
Same journal

The knee

Bailliere's clinical rheumatology·1999
Same journal

The elbow, forearm, wrist and hand

Bailliere's clinical rheumatology·1999
Same journal

Shoulder disorders: a state-of-the-art review

Bailliere's clinical rheumatology·1999
Same journal

The neck

Bailliere's clinical rheumatology·1999
Same journal

Treatment options for regional musculoskeletal pain: what is the evidence?

Bailliere's clinical rheumatology·1999
See all related articles

Area of Science:

  • Endocrinology
  • Bone Biology
  • Menopause Research

Background:

  • Menopause-induced oestrogen deficiency accelerates bone loss by increasing bone turnover and osteoclast activity.
  • Hormone replacement therapy (HRT) is known to counteract these menopausal bone changes.
  • The precise extent of fracture risk reduction with HRT requires further quantification.

Purpose of the Study:

  • To review the effects of hormone replacement therapy (HRT) on bone loss and fracture risk in postmenopausal women.
  • To discuss the optimal duration and long-term extraskeletal effects of HRT, including cardiovascular and breast cancer risks.
  • To explore emerging therapeutic options like tissue-selective oestrogen agonists for managing menopausal health.

Main Methods:

  • Literature review of studies on oestrogen deficiency, HRT, bone metabolism, and extraskeletal effects.

Related Experiment Videos

  • Analysis of evidence regarding fracture risk reduction, cardiovascular outcomes, and breast cancer risk associated with HRT.
  • Evaluation of the role of progestogens and the potential of novel therapies such as selective estrogen receptor modulators (SERMs).

    • Main Results:

    • HRT effectively reverses bone loss and reduces fracture risk at multiple sites, though the magnitude is not fully established.
    • Long-term or lifelong HRT may be necessary for sustained fracture protection.
    • Extraskeletal effects include cardiovascular protection, but breast cancer risk may increase, particularly with current use; progestogen impact is debated.

    Conclusions:

    • HRT is a viable option for preventing menopausal bone loss and fractures, with potential cardiovascular benefits.
    • The need for continuous therapy and the long-term risks (e.g., breast cancer) require careful consideration.
    • Novel therapies like tissue-selective oestrogen agonists hold promise for effective, safer long-term menopausal management.